Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases
Ragini Vittal, Hengmin Zhang, MeiLan K. Han, Bethany B. Moore, Jeffrey C. Horowitz and Victor J. Thannickal
Journal of Pharmacology and Experimental Therapeutics April 2007, 321 (1) 35-44; DOI: https://doi.org/10.1124/jpet.106.113407
Ragini Vittal
Hengmin Zhang
MeiLan K. Han
Bethany B. Moore
Jeffrey C. Horowitz
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases
Ragini Vittal, Hengmin Zhang, MeiLan K. Han, Bethany B. Moore, Jeffrey C. Horowitz and Victor J. Thannickal
Journal of Pharmacology and Experimental Therapeutics April 1, 2007, 321 (1) 35-44; DOI: https://doi.org/10.1124/jpet.106.113407
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases
Ragini Vittal, Hengmin Zhang, MeiLan K. Han, Bethany B. Moore, Jeffrey C. Horowitz and Victor J. Thannickal
Journal of Pharmacology and Experimental Therapeutics April 1, 2007, 321 (1) 35-44; DOI: https://doi.org/10.1124/jpet.106.113407
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement